Feedback PLC Director Dealing (3158R)
2023年10月26日 - 1:53AM
RNSを含む英国規制内ニュース (英語)
TIDMFDBK
RNS Number : 3158R
Feedback PLC
25 October 2023
25 October 2023
Feedback plc
Director/PDMR Dealing
Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the
clinical infrastructure specialist, was informed on 24 October 2023
that on 7 September 2023, 5,422 ordinary shares of 50 pence each in
capital of the Company ("Ordinary Shares") held by Annemijn
Eschauzier, Non-Executive Director of the Company, were
inadvertently sold at a price of 87.1 pence per Ordinary Share.
This sale was made inadvertently due to a clerical error by the
administrator of Annemijn Eschauzier's investment account during a
transition of Annemijn Eschauzier's wider investment portfolio.
Annemijn Eschauzier did not provide instruction for this sale to
take place. Annemijn Eschauzier intends to repurchase the 5,422
Ordinary Shares.
Following this sale of Ordinary Shares, Annemijn Eschauzier
holds an interest in 18 Ordinary Shares in the Company,
representing 0.00% of the Company's issued share capital.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS
DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY
ASSOCIATED WITH THEM
Details of the person discharging managerial responsibilities
1 / person closely associated
a) Names Annemijn Eschauzier
------------------------------------- ---------------------------------------------------
Reason for the notification
2
------------------------------------------------------------------------------------------
a) Position/status Non-Executive Director
------------------------------------- ---------------------------------------------------
b) Initial notification Initial notification
/Amendment
------------------------------------- ---------------------------------------------------
Details of the issuer, emission allowance market participant,
3 auction platform, auctioneer or auction monitor
------------------------------------------------------------------------------------------
a) Name Feedback plc
------------------------------------- ---------------------------------------------------
b) LEI 213800UGOF2GT2U2RV90
------------------------------------- ---------------------------------------------------
Details of the transaction(s): section to be repeated
4 for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
------------------------------------------------------------------------------------------
a) Description of Ordinary Shares of 50 pence each in Feedback
the financial plc
instrument, type
of instrument
Identification GB00BJN59X09
code
------------------------------------- ---------------------------------------------------
b) Nature of the Sale of Ordinary Shares
transaction
------------------------------------- ---------------------------------------------------
c) Price(s) and volume(s)
------------------------- ---------------------
Price(s) Volume(s)
------------------------- ---------------------
87.1 pence 5,422
-------------------------------------------------------------------- ---------------------
d) Aggregated information
- Aggregated volume n/a
- Price
e) Date of the transaction 7 September 2023
------------------------------------- ---------------------------------------------------
f) Place of the transaction XLON
------------------------------------- ---------------------------------------------------
- Ends -
Enquiries:
Feedback plc +44 (0) 20 3997 7634
Tom Oakley, CEO IR@fbk.com
Anesh Patel, CFO
Panmure Gordon (UK) Limited (NOMAD
and Broker)
Emma Earl/Freddy Crossley (Corporate
Finance)
Rupert Dearden (Corporate Broking) +44 (0)20 7886 2500
Walbrook PR Ltd; Tel: 020 7933 8780 or feedbackplc@walbrookpr.com
Nick Rome/Joe Walker 07748 325 236 or 07407 020
470
About Feedback
Feedback plc helps clinical teams to make better decisions
faster for patients. We design products that enhance clinician
access to patient data and to their colleagues. Our unique approach
centres around individual patient episodes, into which we pull
relevant clinical data from hospital systems and around which we
build remote clinical teams for collaboration. As a result, we
produce a digital infrastructure that makes patient data available
to clinicians in multiple settings, in a format that enables them
to meaningfully interact with it, providing flexibility to
clinicians and free movement of patients between provider settings
- clinicians can practice from anywhere and patients can attend any
care provider for treatment.
Our products Bleepa and CareLocker work together to deliver
unparalleled value to our customers. Bleepa is our application
layer and sits on top of CareLocker as our data layer. Bleepa is a
clinician facing platform that displays clinical results from a
patient's CareLocker at a certified and regulated quality, that is
suitable for clinical use and enables dialogue on a
patient-by-patient basis with colleagues through a secure,
auditable chat interface that links back to the patient medical
record. The CareLocker data storage model is built around the
patient. Our vision is one where relevant clinical data is always
available to the patient as well as to any care setting that they
may attend - a federated data architecture with the patient as the
tenant.
The Company has a number of growth opportunities domestically
and internationally across a range of markets including the NHS,
the veterinary market and private healthcare providers and its
highly scalable Software as a Service ("SaaS")-based model is
expected to provide increasing levels of revenue visibility as the
Company grows its customer base.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHPPGUAUUPWGQA
(END) Dow Jones Newswires
October 25, 2023 12:53 ET (16:53 GMT)
Feedback (LSE:FDBK)
過去 株価チャート
から 11 2024 まで 12 2024
Feedback (LSE:FDBK)
過去 株価チャート
から 12 2023 まで 12 2024